文献速递临床免疫分子诊断临床微生物

Quidel Sofia SARS FIA检测与Hologic Aptima SARS-CoV-2 TMA检测在有症状门诊患者COVID-19诊断中的比较

Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients.
PubMed 文献 · J Clin Microbiol · 2021-01-21

本研究在有症状门诊患者中平行比较Quidel Sofia SARS FIA快速抗原检测与Hologic Aptima SARS-CoV-2 TMA分子检测。以CT值≤35作为培养阳性的替代指标,SOFIA在≤5天患者中检测到87.2%可能培养阳性者。

要点

  • SOFIA抗原检测在症状出现≤5天时阳性符合率为82.0%,>5天降至54.5%。
  • 以CT≤35为培养阳性替代,SOFIA在≤5天患者中检出87.2%可能培养阳性者。
  • 症状出现超过5天后SOFIA抗原检测敏感性明显下降。

核心结论

  • SOFIA抗原检测在有症状患者症状出现≤5天时与APTIMA TMA分子检测的阳性符合率为82.0%,>5天时为54.5%。
  • 以CT值≤35作为SARS-CoV-2培养阳性的替代指标,SOFIA在≤5天患者中检测到87.2%可能培养阳性者。

研究设计与样本

  • 对SOFIA与APTIMA TMA结果不一致的标本,采用Cepheid Xpert Xpress SARS-CoV-2 RT-PCR检测CT值。

主要发现

  • SOFIA对症状出现≤5天患者的阳性符合率为82.0%,对>5天患者为54.5%。
  • 以CT值≤35作为培养阳性替代,SOFIA在≤5天患者中检测到87.2%可能培养阳性者。

关键数值与推荐

  • 阳性符合率(PPA):症状出现≤5天为82.0%,>5天为54.5%。
  • CT值≤35作为SARS-CoV-2培养阳性的替代指标,SOFIA在≤5天患者中检出87.2%可能培养阳性者。

临床怎么用

  • 有症状患者症状出现≤5天时可考虑使用SOFIA抗原检测,但阴性结果仍需分子检测确认。
  • 症状出现超过5天时SOFIA阳性符合率仅54.5%,应优先采用分子检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Quidel Sofia severe acute respiratory syndrome (SARS) fluorescent immunoassay (FIA) test (SOFIA) is a rapid antigen immunoassay for the detection of SARS coronavirus 2 (SARS-CoV-2) proteins from nasal or nasopharyngeal swab specimens. The purpose of this study was to compare the results of the SOFIA test to those of the Hologic Aptima SARS-CoV-2 TMA test (APTIMA TMA), a high-throughput molecular diagnostic test that uses transcription-mediated amplification (TMA) for the detection of SARS-CoV-2 nucleic acid from upper respiratory tract specimens. Three hundred forty-seven symptomatic patients from an urgent care center in an area with a high prevalence of SARS-CoV-2 infections were tested in parallel using nasal swabs for the SOFIA test and nasopharyngeal swabs for the APTIMA TMA test. The SOFIA test demonstrated a positive percent agreement (PPA) of 82.0% with the APTIMA TMA test for symptomatic patients tested ≤5 days from symptom onset and a PPA of 54.5% for symptomatic patients >5 days from symptom onset. The Cepheid Xpert Xpress SARS-CoV-2 reverse transcription-PCR (RT-PCR) test was used to determine the cycle threshold (CT ) value for any specimens that were discrepant between the SOFIA and APTIMA TMA tests. Using a CT value of ≤35 as a surrogate for SARS-CoV-2 culture positivity, we estimate that the SOFIA test detected 87.2% of symptomatic patients tested ≤5 days from symptom onset who were likely to be culture positive.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Beck ET, Paar W, Fojut L, et al. Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients. J Clin Microbiol. 2021. PMID: 33239376. doi:10.1128/JCM.02727-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。